ADAMTSL5 serves as both an activated antigen for CD8 + IL‐17 T cells in psoriasis and, as demonstrated in Arechederra et al.'s study [20], plays a role in sustaining vital oncogenic signaling pathways, indicating its pivotal role in tumorigenesis and resistance in HCC. Here, CD8A is linked to psoriasis.